NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) securities during the period of September 13, 2022 through Ocober 9, 2023, inclusive (“the Class Period”).

2024年5月3日，纽约（环球通讯社）--Kirby McInerney LLP律师事务所宣布，已代表收购Akero Therapeutics，Inc.（“Akero”或“公司”）（纳斯达克：AKRO）证券的人在2022年9月13日至2023年5月9日（含）期间向美国加州北区地方法院提起集体诉讼。

Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here to learn more about the class action] On October 10, 2023, Akero disclosed the results of its Phase 2b SYMMETRY study, which the Company had represented would research the effect of its lead drug candidate EFX on treating nonalcoholic steatohepatitis (NASH) induced cirrhosis.

投资者必须在2024年6月25日之前向法院申请被指定为诉讼的主要原告。[点击此处了解有关集体诉讼的更多信息]2023年10月10日，Akero披露了其2b期对称性研究的结果，该公司代表该研究将研究其主要候选药物EFX对治疗非酒精性脂肪性肝炎（NASH）引起的肝硬化的影响。

Akero filed with the SEC a Form 8-K and issued a press release stating that the SYMMETRY study had failed to meet its primary endpoint. In an investor call that same day, the Company admitted that its pretrial protocol had specified that cryptogenic cirrhotics would be excluded from the secondary endpoint calculation, despite the fact that this information was contrary to what the Company had told investors regarding the trial’s design.

阿克罗向美国证券交易委员会提交了一份表格8-K，并发布了一份新闻稿，指出对称性研究未能达到其主要终点。在同一天的一次投资者电话会议上，该公司承认，其预审协议规定，隐源性肝硬化将被排除在次要终点计算之外，尽管这些信息与该公司告诉投资者的试验设计相反。

On this news, the price of Akero shares declined by $30.39 per share, or approximately 62.6%, from $48.54 per share on October 9, 2023 to close at $18.15 on October 10, 2023. The lawsuit alleges that throughout the Class Period, Akero made false and/or misleading statements and/or failed to disclose that: (i) approximately 20% of the patients enrolled in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensate.

根据这条消息，阿克罗的股价从2023年10月9日的每股48.54美元下跌至2023年10月10日的每股18.15美元，下跌了30.39美元，跌幅约为62.6%。该诉讼声称，在整个上课期间，Akero做出了虚假和/或误导性陈述和/或未能披露：（i）参加SYMMETRY研究的患者中约有20%患有隐源性肝硬化，并且在基线时没有明确的NASH；（ii）SYMMETRY研究中包括的隐源性肝硬化患者没有活检证实的补偿。